San Antonio Breast Cancer Symposium (SABCS 2024)

Gilberto Amorim (Brasil) - 1L ribociclib + ET versus combo CT en cáncer de mama avanzado HR+/HER2− clínicamente agresivo: un análisis de subgrupos de RIGHT Choice

 

First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive HR+/HER2− advanced breast cancer (ABC): a subgroup analysis of RIGHT Choice by intrinsic subtype and gene and signature expresión

FA-11324982